Ribovax Biotechnologies S.A.

https://www.ribovax.com
Link has been incorrect on 2015-04-20

ribOvax Biotechnologies SA is a privately held company dedicated to the development of innovative antibody technology platforms and products in areas with clearly identified medical needs. Ribovax owns two proprietary technology platforms in the field of antibody engineering that have already delivered patented therapeutic and diagnostic fully human monoclonal antibodies. Ribovax has produced proprietary antibodies in the field of infectious diseases (HSV 1 and 2, CMV, Rubella, VZV) and oncology (anti-Alpha Enolase). *

	Start	2011-09-06 existent
	Industry	BIOTECH

	Region	Genève (Geneva) GE
	Country	Switzerland
	Street	12 Avenue des Morgines
	City	1213 Petit-Lancy, Genève
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)